Sionna Therapeutics, Inc. (SION): Cash & Equivalents
$58.45M
As of 2025-12-31
$63.32M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $58.45M | +54.7% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $37.79M | n/a | 2026-03-02, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $58.45M | +54.7% |
| Omeros Corp (OMER) | 2025-12-31 | $9.66M | +184.1% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $307.53M | -34.8% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $41.32M | -18.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $190.68M | +8.0% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $261.34M | +4.2% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $77.56M | -52.6% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $226.65M | +192.9% |
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $45.54M | -38.7% |
Compare SION, OMER, PRTA, SPRY side by side · Screen every company in Pharmaceutical Preparations ↗